These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 30389991)

  • 1. TRIAMF: A New Method for Delivery of Cas9 Ribonucleoprotein Complex to Human Hematopoietic Stem Cells.
    Yen J; Fiorino M; Liu Y; Paula S; Clarkson S; Quinn L; Tschantz WR; Klock H; Guo N; Russ C; Yu VWC; Mickanin C; Stevenson SC; Lee C; Yang Y
    Sci Rep; 2018 Nov; 8(1):16304. PubMed ID: 30389991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
    Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
    Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical Modification of Guide RNAs for Improved CRISPR Activity in CD34+ Human Hematopoietic Stem and Progenitor Cells.
    Shapiro J; Tovin A; Iancu O; Allen D; Hendel A
    Methods Mol Biol; 2021; 2162():37-48. PubMed ID: 32926376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome editing in human hematopoietic stem and progenitor cells via CRISPR-Cas9-mediated homology-independent targeted integration.
    Bloomer H; Smith RH; Hakami W; Larochelle A
    Mol Ther; 2021 Apr; 29(4):1611-1624. PubMed ID: 33309880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
    Wilbie D; Walther J; Mastrobattista E
    Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells.
    Yudovich D; Bäckström A; Schmiderer L; Žemaitis K; Subramaniam A; Larsson J
    Sci Rep; 2020 Dec; 10(1):22393. PubMed ID: 33372184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome Engineering of Hematopoietic Stem Cells Using CRISPR/Cas9 System.
    Devaraju N; Rajendiran V; Ravi NS; Mohankumar KM
    Methods Mol Biol; 2022; 2429():307-331. PubMed ID: 35507170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas9-Mediated ELANE Mutation Correction in Hematopoietic Stem and Progenitor Cells to Treat Severe Congenital Neutropenia.
    Tran NT; Graf R; Wulf-Goldenberg A; Stecklum M; Strauß G; Kühn R; Kocks C; Rajewsky K; Chu VT
    Mol Ther; 2020 Dec; 28(12):2621-2634. PubMed ID: 32822592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models.
    Demirci S; Khan MBN; Hinojosa G; Le A; Leonard A; Essawi K; Gudmundsdottir B; Liu X; Zeng J; Inam Z; Chu R; Uchida N; Araki D; London E; Butt H; Maitland SA; Bauer DE; Wolfe SA; Larochelle A; Tisdale JF
    Cytotherapy; 2024 Jun; 26(6):641-648. PubMed ID: 38506770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin.
    Métais JY; Doerfler PA; Mayuranathan T; Bauer DE; Fowler SC; Hsieh MM; Katta V; Keriwala S; Lazzarotto CR; Luk K; Neel MD; Perry SS; Peters ST; Porter SN; Ryu BY; Sharma A; Shea D; Tisdale JF; Uchida N; Wolfe SA; Woodard KJ; Wu Y; Yao Y; Zeng J; Pruett-Miller S; Tsai SQ; Weiss MJ
    Blood Adv; 2019 Nov; 3(21):3379-3392. PubMed ID: 31698466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9.
    Gundry MC; Brunetti L; Lin A; Mayle AE; Kitano A; Wagner D; Hsu JI; Hoegenauer KA; Rooney CM; Goodell MA; Nakada D
    Cell Rep; 2016 Oct; 17(5):1453-1461. PubMed ID: 27783956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies.
    Ureña-Bailén G; Block M; Grandi T; Aivazidou F; Quednau J; Krenz D; Daniel-Moreno A; Lamsfus-Calle A; Epting T; Handgretinger R; Wild S; Mezger M
    CRISPR J; 2023 Feb; 6(1):5-16. PubMed ID: 36662546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates.
    Humbert O; Radtke S; Samuelson C; Carrillo RR; Perez AM; Reddy SS; Lux C; Pattabhi S; Schefter LE; Negre O; Lee CM; Bao G; Adair JE; Peterson CW; Rawlings DJ; Scharenberg AM; Kiem HP
    Sci Transl Med; 2019 Jul; 11(503):. PubMed ID: 31366580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescent labeling of CRISPR/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response.
    Nasri M; Mir P; Dannenmann B; Amend D; Skroblyn T; Xu Y; Schulze-Osthoff K; Klimiankou M; Welte K; Skokowa J
    Blood Adv; 2019 Jan; 3(1):63-71. PubMed ID: 30622144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34
    Katta V; O'Keefe K; Li Y; Mayuranathan T; Lazzarotto CR; Wood RK; Levine RM; Powers A; Mayberry K; Manquen G; Yao Y; Zhang J; Jang Y; Nimmagadda N; Dempsey EA; Lee G; Uchida N; Cheng Y; Fazio F; Lockey T; Meagher M; Sharma A; Tisdale JF; Zhou S; Yen JS; Weiss MJ; Tsai SQ
    Mol Ther; 2024 Oct; 32(10):3433-3452. PubMed ID: 39086133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
    Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
    Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications.
    Venkatesan V; Christopher AC; Karuppusamy KV; Babu P; Alagiri MKK; Thangavel S
    J Vis Exp; 2022 Aug; (186):. PubMed ID: 36036597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized Guide RNA Selection Improves
    Verhagen HJMP; Kuijk C; Rutgers L; Kokke AM; van der Meulen SA; van Mierlo G; Voermans C; van den Akker E
    CRISPR J; 2022 Oct; 5(5):702-716. PubMed ID: 36169633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and Validation of CRISPR/Cas9 Off-Target Activity in Hematopoietic Stem and Progenitor Cells.
    Park SH; Lee CM; Bao G
    Methods Mol Biol; 2022; 2429():281-306. PubMed ID: 35507169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly Efficient Mouse Genome Editing by CRISPR Ribonucleoprotein Electroporation of Zygotes.
    Chen S; Lee B; Lee AY; Modzelewski AJ; He L
    J Biol Chem; 2016 Jul; 291(28):14457-67. PubMed ID: 27151215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.